Patent Application
20120122984
In the United States it is estimated that 60% of adults meet the clinical requirements to be considered overweight or clinically obese resulting in 300,000 deaths annually. See, Eberhardt et al., Urban and rural health chartbook. 2001, Health, United States Hyattsville (MD): NCHS. p. 296; General, The Surgeon General's call to action to prevent and decrease overweight and obesity:2001, R.M. U.S. Department Health and Human Services, Editor. 2001. In 2001, the Surgeon General of the United States issued a call to action to prevent and decrease the incidence and prevalence of individuals that are overweight or clinically obese. The Surgeon General's call to action to prevent and decrease overweight and obesity:2001, R.M. U.S. Department Health and Human Services, Editor. 2001. Interestingly, in this report there is no mention of the application or use of a pharmaceutical approach to the problem. However, there is a great deal of interest in the development of a pharmaceutical approach by both industrial and academic research institutions. The pharmaceutical approach is attractive since there is a strong likelihood of greater compliance due to the probable ease of application and use.
Epidemiological studies from around the world have demonstrated an incontrovertible correlation between mortality and obesity. The progress that has been made over the past 50 years in achieving our health goals with regard to prevention and control of infectious diseases, heart disease, diabetes and certain cancers has been largely wiped out by the growing epidemic of obesity. In 2001, approximately 25% of children and teenagers were overweight, over twice the percentage from just 20 years ago. Currently, well over 60% of adults are found to be overweight or obese, and over 300,000 deaths per year can be directly attributed to these conditions in the U.S. alone. These findings cut across all races, ages, ethnic groups and both genders, although certain groups, particularly minority and low socioeconomic groups, are clearly more prone than others. The Surgeon General's call to action to prevent and decrease overweight and obesity:2001, R.M. U.S. Department Health and Human Services, Editor. 2001.
Overweight, defined as a body mass index (BMI ranging from 25-29.9 kg/m2) and obesity (BMI>30 kg/m2), has been correlated with premature death, type 2 diabetes, heart disease, stroke, hypertension, gallbladder disease, osteoarthritis, sleep apnea, asthma, various breathing problems, certain cancers, high blood cholesterol, pregnancy complications, increased surgical risk, psychological disorders, and other pathological conditions too numerous to list. The Surgeon General's call to action to prevent and decrease overweight and obesity:2001, R.M. U.S. Department Health and Human Services, Editor. 2001; NHLBI, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults, N. NIH, Editor. 1998, HHS, PHS. p. 29-41. Obese individuals have a 50-100% increased risk of premature death from all these causes compared to persons with a BMI in the normal range (20-25 kg/m2). Even modest weight loss (5-15% of excess total body weight) reduces the risk factors for a least some of these diseases, particularly heart disease, in the short term. NHLBI, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults, N. NIH, Editor. 1998, HHS, PHS. p. 29-41. Current evidence suggests that the effect may have long-term benefits as well. See id.; NIDDK, Study of health outcomes of weight-loss (SHOW) trial, NIDDK, Editor. 2001, National Institutes of Health, U.S.A.
The Surgeon General's 2001 call to action to prevent and decrease overweight and obesity emphasizes the obvious changes in the American lifestyle during the past several decades, with an ever-increasing reliance on sources of poor nutrition and an increased sedentary lifestyle. His principal call to action is to promote education in the schools and throughout the community to encourage healthy eating and regular, adequate exercise. At this point in the ongoing process, it seems very likely that the vast majority of U.S. citizens have at least a cursory knowledge of this important message. However, the current trend toward obesity shows no signs of abating, and, in fact, is predicted to worsen over time. Clearly, the main obstacle to overcome is the need for compliance with regard to diet and exercise according to directed guidelines by the general population, which represents a dim prospect.
It is an interesting feature of the Surgeon General's 2001 report that essentially no mention is made of pharmaceutical approaches to the prevention and cure of overweight and obesity. Obviously, this is a keen area of interest among both academic and industrial institutions, since such an approach potentially could reduce the need for patient compliance. Enormous progress has been made in recent years in understanding the roles and functions of adipose tissue (reviewed by Frayn et al., Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord, 2003. 27(8): p. 875-88), both from the standpoints of regulation of energy storage and as a secretory cell. The picture that has emerged is very complex, since it involves the activity of the autonomic nervous system, the delivery of complex mixtures of substrates and hormones, feedback from autocrine and paracrine effectors secreted by adipocytes and also vascular supply to the fat tissue. Also, factors such as leptin and adiponectin secreted by adipocytes have a general effect on general metabolism. See, Guerre-Millo, Adipose tissue hormones. J Endocrinol Invest, 2002. 25(10):855-61; Kishida, Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. Biochem Biophys Res Commun, 2003. 306(1):286-92; Miner, The adipocyte as an endocrine cell. J Anim Sci, 2004. 82(3):935-41; Rabin, et al., Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther, 2005. 3(3):465-71; Houseknecht et al., The biology of leptin: a review. J Anim Sci, 1998. 76(5):1405-20; Mantzoros, The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med, 1999. 130(8):671-80.
From this, it is clear that a very integrative, holistic approach is required to gain a full understanding of the normal and pathological states that form the basis for the current problem with overweight and obesity described above.
Many types of animals are used for research, agriculture and companionship. In some instances the costs of housing and feeding such animals is great. Smaller-sized animals would cost less to feed and house than normal sized animals. Therefore, compositions and methods of producing reduced-sized animal(s) and/or reduced weight animal(s) can be advantageous. Also, obesity in companion animals is a problem. Obesity can cause shortened lifespan and many of the same diseases and conditions mentioned above for humans.
Lipomas are benign tumors composed of fat cells in thin, fibrous capsules that are usually found just below the skin. Lipomas can occur almost anywhere in the body, but are found most often on the torso, neck, upper thighs, upper arms, and armpits. Lipomas are the most common type of non-malignant soft tissue tumor. Lipomas occur in many animals, but are most common in dogs. Cattle and horses, cats and pigs are susceptible to lipoma development. Lipoma types include: superficial subcutaneous, intramuscular, spindle cell, angiolipoma, benign lipoblastoma, and lipoma of tendon sheath, nerves, or synovium.
The cause of lipomas is not completely known, but the tendency to develop lipomas can be inherited. For example, hereditary conditions, such as familial multiple lipomatosis, can include lipoma development. A correlation between the HMG I-C gene (previously identified as a gene related to obesity) and lipoma development has been demonstrated in mice. Additionally, minor injuries may trigger their growth. Currently, there is no known treatment to prevent lipomas or affect their growth. Lipomas are usually surgically removed where the lipoma becomes painful or tender, becomes infected or inflamed repeatedly, drains foul-smelling discharge, interferes with movement or function, increases in size or becomes unsightly or bothersome. Liposuction can also be used to remove lipomas.
Malignant transformation of lipomas into liposarcomas is rare, although a few cases of malignant transformation have been described in, for example, bone and kidney lipomas. Methods for the treatment of lipomas and liposarcomas are needed in the art.
In one embodiment the invention provides a method for treatment of a lipoma in a mammal comprising administering glycine to the lipoma. The glycine can comprise glycine analogs or a combination of glycine and glycine analogs. The mammal can be a human, a dog, a cat, a bovine, a pig or a horse. The glycine can be administered to the lipoma by injection into the lipoma or through oral administration. Where injected, the glycine can be present in a pharmaceutically acceptable carrier at a concentration of about 0.1 mg/ml to about 15 mg/ml. Where the glycine is administered orally to the mammal, the glycine can be in a pharmaceutically acceptable carrier or food, beverage or dietary supplement at about 10% to 30% by weight of the diet of the mammal.
Another embodiment of the invention provides a method for treatment of a liposarcoma in a mammal comprising administering glycine to the liposarcoma. The glycine can comprise glycine analogs or a combination of glycine and glycine analogs. The mammal can be a human, a dog, a cat, a bovine, a pig or a horse. The glycine can be administered to the liposarcoma by injection into the liposarcoma. The glycine can be present in a pharmaceutically acceptable carrier at a concentration of about 0.1 mg/ml to about 15 mg/ml. Even another embodiment of the invention provides a method for treatment of a liposarcoma in a mammal comprising administering glycine orally to the mammal. The glycine can be combined with a pharmaceutically acceptable carrier or food, beverage, or dietary supplement at about 10% to 30% by weight of the diet of the mammal.
Still another embodiment of the invention provides a method for reducing white adipose tissue in an overweight or obese animal. The method comprises administering a high glycine food, beverage, or dietary supplement product comprising 10% to 30% glycine by weight of the food, beverage, or dietary supplement product to the animal, wherein white adipose tissue in the overweight or obese animal is reduced.
Yet another embodiment of the invention provides a method for producing weight loss in an overweight or obese animal. The method comprises administering a high glycine food, beverage, or dietary supplement product comprising 10% to 30% glycine by weight of the food, beverage or dietary supplement product to the overweight or obese animal, wherein weight loss in the overweight or obese animal is produced. The method for producing weight loss can comprise reducing fat content in the overweight or obese animal. The animal can be a human. The food or beverage product can be a meal replacement drink, a granola bar or a flavored drink mix.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.
It has been discovered that a common amino acid, glycine, which when added to the diet of laboratory animals has the effect of causing a dose-dependent loss in weight. The effect has been observed in a number of rodent strains and in dogs. At optimal doses, and indeed at super-optimal doses, no deleterious side-effects were observed during prolonged administration. Glycine is a non-essential amino acid synthesized by most mammals from serine that arises from the glycolytic pathway as part of normal intermediary metabolism. It is a compound that has been extensively studied in its native and derivative forms with regard to its role in the origin and possible treatment of several mental disorders, particularly schizophrenia (see, e.g, Waziri & Baruah, A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings. Schizophr Res, 1999. 37(3):205-15; Waziri, Glycine therapy of schizophrenia. Biol Psychiatry, 1988. 23(2):210-1; Waziri, Glycine therapy of schizophrenia: some caveats. Biol Psychiatry, 1996. 39(3):155-6; Javitt, Glycine therapy of schizophrenia. Biol Psychiatry, 1996. 40(7):684-6; Javitt, Glycine modulators in schizophrenia. Curr Opin Investig Drugs, 2002. 3(7):1067-72; Shoham et al., Chronic high-dose glycine nutrition: effects on rat brain cell morphology. Biol Psychiatry, 2001. 49(10):876-85; Javitt, Management of negative symptoms of schizophrenia. Curr Psychiatry Rep, 2001. 3(5):413-7; Shoham et al., High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum. Int J Neuropsychopharmcol, 1999. 2(1):35-40; Shoham, et al., Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. Brain Res, 2004. 1004(1-2):142-7; Tuominen et al., Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res, 2005. 72(2-3):225-34). In several of these reports, an effect of glycine administration is noted to have a small but significant impact on weight of test animals or subjects, but this observation never became the subject of speculation or further analysis. This is probably because the observed effects were relatively small, possibly due to the counteracting effects of other medications. Petzke et al. (1987) reported that glycine has a relatively high thermogenic effect as compared to other amino acids, sugars and fats, which correlated with increased oxygen uptake. Petzke & Albrecht, [The effect of nutrition on the metabolism of glycine]. Nahrung, 1987. 31(2):157-72; Petzke et al., Utilization of [1-14C] carbon of glycine of high glycine diet fed young and old rats, Zfa, 1987. 42(6): p. 323-8; Petzke et al., [The effect of oral administration of glycine on metabolism]. Nahrung, 1987. 31(3): p. 207-15. His group noted a dose-dependent reduction in the growth of experimental rats, but was not able to provide a biochemical basis for the possible mechanism. In addition to replicating this finding, as described below, we have demonstrated that adult animals show a dose-dependent weight loss with glycine supplementation of their diets. Glycine or glycine analogs can be used to combat obesity without observable adverse side-effects. Additionally, glycine acts to induce apoptosis specifically in adipose cells, probably using a heretofore unrecognized pathway.
Glycine is a readily available, non-toxic amino acid. Glycine, glycine analogs, or a combination thereof can be used in the methods of the invention. Any glycine analog that induces apoptosis, directly or indirectly, in adipose cells, such as white adipose cells can be used. In one embodiment of the invention a glycine analog can comprise Formula I.
For example, in Formula I:
Other glycine analogs can comprise Formula II:
For example, in Formula II:
In another embodiment of the invention glycine analogs can comprise Formula III:
In one embodiment of the invention R1, R2, and R3 of Formulas I, II, and IIII are independently selected from (CH2)0-5H.
A “high glycine diet” is a diet high in glycine, a glycine analog or analogs, or combinations thereof, or high dosages of glycine supplements, glycine analog supplements or combinations thereof. In one embodiment of the invention glycine analogs or glycine analogs combined with glycine produces a physiologic effect about the same as that obtained when a diet comprising only glycine is administered. That is, glycine analogs or the combination of glycine and glycine analogs produce a physiologic concentration of glycine in the animal that is about the same as the physiologic concentration of glycine in the animal when glycine is administered to the animal in a high glycine diet. In some instances glycine analogs or glycine analogs in combination with glycine can be administered at a lower percentage than glycine alone to achieve a similar effect as when glycine is used alone. For example, glycine analogs or glycine analogs in combination with glycine can be administered in a diet at about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, percent or more by weight.
The glycine and glycine analogs can be mixed into the diet or administered by other routes. The supplements can be liquid, semi-solid, solid or any other form. A high glycine diet comprises about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40%, or more by weight of glycine, glycine analogs or combinations thereof. In one embodiment of the invention a high glycine diet can comprise about 5% to about 40% or more, about 10% to about 40%; about 10% to about 30%; about 15% to about 25%; or about 20% to about 25% glycine, or glycine analogs or combinations thereof.
The invention also provides a diet composition for weight reduction in an animal comprising about 3.5% to about 40% or more, about 3.5% to about 40%; about 10% to about 30%; about 15% to about 25%; or about 20% to 25% glycine, glycine analogs or combinations thereof (i.e., about 3.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40%, or more by weight of glycine, glycine analogs or combinations thereof) and about 60% to about 96.5% (i.e., about 96.5, 95, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 75, 70, 65, or 60%) of a diet that is low in calories.
The invention also provides a diet composition for weight reduction in an animal comprising about 3.5% to about 40% or more; about 10% to about 40% or more; about 10% to about 30%; about 15% to about 25%; or about 20% to 25% glycine, glycine analogs or combinations thereof (i.e., about 3.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40%, or more by weight of glycine, glycine analogs or combinations thereof) and about 60% to about 96.5% (i.e., about 96.5, 95, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 75, 70, 65, or 60%) of a diet that is low in fat. The low-fat diet can be a low saturated fat diet.
The invention also provides a diet composition for weight reduction in an animal comprising about 3.5% to about 40% or more; 10% to about 40% or more; about 10% to about 30%; about 15% to about 25%; or about 20% to 25% glycine, glycine analogs or combinations thereof (i.e., about 3.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40%, or more by weight of glycine, glycine analogs or combinations thereof) and about 60% to about 96.5% (i.e., about 96.5, 95, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 75, 70, 65, or 60%) of a diet that is low in carbohydrates.
The administration of high glycine diet to a male or female animal, such as a human, can induce apoptosis in adipose tissue, in particular, white adipose tissue of the animal. Therefore, the high glycine diet can reduce adipose tissue or reduce adipose cell size or both in the animal. Methods of the invention comprise administering a high glycine diet to an animal to induce apoptosis in adipose tissue, reduce adipose tissue, reduce adipose cell size, or combinations thereof in the animal. The animal can be overweight, obese, or normal weight.
While not wishing to be bound to a particular theory, it is believed that the induction of apoptosis in adipose tissue is caused by the direct or indirect effect of glycine. This mechanism of action is supported by the observed effects that such a diet has on BAD, a pro-apoptotic member of the Bcl-2 family. BAD's ability to promote cell death is inhibited by phosphorylation at position 136. The administration of a high glycine diet reduces or eliminates phosphorylation of BAD at position 136 in adipose tissue indicating that the loss of adipose tissue observed when a high glycine diet or its equivalent is administered occurs through induction of apoptosis.
The administration of a high concentration of glycine either in the diet (i.e., orally) or via other means of administration can reduce abdominal fat content in an animal. Additionally, the administration of glycine either in the diet or via other means of administration to an animal can produce weight loss in the animal. However, upon initial administration of a diet supplemented with glycine, a weight gain may be seen. While not wishing to be bound by any particular theory, it is believed that this observation may be a result of the loss of fat tissue and the gain of muscle tissue.
The methods and compositions of the invention can be used to produce reduced-sized and or reduced-weight animals. For example, animals that are about 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 75% smaller than normal-sized animals or about 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 75% lighter than normal-weight animals. A normal-sized or normal-weight animal is an animal that falls within an average or typical weight or size range for the animal species where age and general health condition are taken into account.
The invention provides methods for producing reduced-sized, or reduced-weight, or both reduced-size and reduced-weight animals comprising administering to the animal a high glycine diet. For reduced-size animals, a high glycine diet is fed to immature animals. The high glycine diet can be administered on a daily basis. The animal can be, for example a human, non-human primate, a rat, a mouse, a rabbit, a guinea pig, a bovine, a pig, a sheep, a goat, a dog, a cat, a horse, a bird or a fish.
The invention also provides methods for producing a reduced-sized animal as described above followed by returning the animal to a normal size. The methods comprise administering a high glycine diet to an immature animal to produce a reduced-sized animal and then administering a normal diet to the animal to produce a normal-sized animal. A normal diet is a diet that is not supplemented with glycine, but contains normal amounts of glycine.
The invention also provides methods for producing a reduced-weight animal and then returning the animal to a normal weight comprising administering a high glycine diet to the mature or immature animal to produce a reduced-weight animal and then administering a normal diet to the animal to produce a normal-weight animal.
Yet another embodiment of the invention provides a method for producing a permanently reduced-sized and or reduced-weight animal through the administration of a high glycine diet to an immature animal to produce a permanently reduced-sized or reduced weight animal. Administration of a high glycine diet can be continued throughout the lifetime of the animal or until further growth is prevented by the physiological processes that normally are associated with cessation of growth.
Methods and compositions of the invention can also be used to produce weight loss in an animal such as an immature or mature animal. Weight loss of about 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 75% can be achieved.
One embodiment of the invention provides a method for producing weight loss in an animal comprising administering to the animal a high glycine diet as described above. The animal can be, for example, a human, a non-human primate, a rat, a mouse, a rabbit, a guinea pig, a bovine, a pig, a sheep, a goat, a dog, a cat, a horse, a bird, a fish or an invertebrate. In one embodiment of the invention, the animal is healthy and has no underlying health problems or issues. In another embodiment of the invention the animal has only an overweight or obesity health problem and no other health problems or issues. The animal can be overweight, obese, or normal weight.
A high glycine diet can be administered with an adjunctive weight loss therapy such as an exercise regimen, a low-fat diet, a low-calorie diet, a low-carbohydrate diet, surgical intervention such as gastroplasty, gastric partitioning, and gastric bypass, behavioral therapy, pharmacotherapy (e.g., use of sibutramine, MERIDIA® (sibutramine HCl monohydrate), XENICAL® (orlistat) and combinations thereof), natural dietary aids or over the counter (OTC) weight-loss products, and combinations thereof. In one embodiment of the invention, a high glycine diet is not a basal diet or other nutritionally incomplete or inadequate diet. A basal diet is a diet fed to a test subject that is complete and adequate except for one or more constituents (e.g., vitamins, minerals, or amino acids), which is omitted for a period and the effects on the subject observed. The subject may be observed for a second period during which the one or more constituents being studied are added to the diet
A low-fat diet is a diet that comprises about 3%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70% or 80% less fat than the normal recommended amount of fat in a diet for a given species of a given age, weight, and general health condition. For example, a low-fat diet in humans can comprise a diet consisting of about 0%, 3%, 5%, 7%, 10%, 13%, 15%, 20% or 25% fat.
A low-calorie diet is a diet that comprises about 3%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70% or 80% less calories than the normal recommended amount of calories for a certain species of a given age, weight, and general health condition.
A low carbohydrate diet is a diet that comprises about 3%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70% or 80% less carbohydrates than the normal recommended amount of calories for a certain species of a given age, weight, and general health condition.
Behavior therapy includes strategies that help in overcoming barriers to compliance with dietary therapy and/or exercise therapy. Such strategies include, for example, self-monitoring of eating habits and exercise, stress management, stimulus control, problem-solving (e.g., self-corrections of problem areas related to eating and exercise), contingency management (e.g., use of rewards for specific desirable actions, cognitive restructuring (e.g., modification of unrealistic goals and inaccurate beliefs), and social support.
Glycine and glycine analogs can be administered, for example, orally, topically, parenterally, by inhalation or spray, or rectally using formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, intraperitoneally or intrathecal injection or infusion techniques and the like. In addition, glycine and glycine analogs can be combined with a pharmaceutically acceptable carrier. Glycine and glycine analogs can be present in association with one or more non-toxic pharmaceutically acceptable carriers, excipients, coloring agents, preservative agents, flavoring agents, diluents, adjuvants or combinations thereof, and if desired other active ingredients. Glycine and glycine analogs can be in any form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, slow release formulations, or syrups or elixirs. Glycine and glycine analogs can be present in food formulations.
Glycine or glycine analogs according to the invention can be added at about 10% to about 30% (w/w or w/v) to any type of food product, beverage product or dietary supplement product, including solid, liquid, or semi-solid products. The total diet of an animal can comprise about 10% to about 30% of glycine or glycine analogs (w/w or w/v) when fed these food, beverage or dietary supplement products. A dietary supplement supplements the diet, contains one or more dietary ingredients (including vitamins, minerals, amino acids, and other substances) or their constituents, and is usually intended to be taken by mouth as a pill, capsule, tablet, or liquid.
Exemplary liquid or semi-liquid food products include, for example, drink mixes (including powdered drink mixes), meal replacement drinks, milk, low-fat milk, soy milk, rice milk, fruit juice, fruit flavored drinks, ready-to-drink beverages, dry-blended beverages, protein drinks or shakes, vegetable-based drinks, coffee-based beverages, sports drinks, soups (including dry soup mixes), semi-solid beverages, and smoothies. Solid food products and dietary supplements include, for example, protein supplements, nutritional supplements, sugar substitute sweeteners, cakes, cookies, filled cookies, pies, breads, rolls, muffins, grains, hard candies, chewy candies, breakfast cereals, crackers, cheese or peanut butter filled cracker snacks, breads, pastas, chips, pretzels, sweet doughs, pastries, cream fillings, yogurts, puddings, cheeses, spreads, salad dressings, margarines, butter, mayonnaise, frozen foods, egg products, ice creams, frozen desserts, frozen yogurts, peanut butters, granolas, granola bars, meal replacement bars, energy bars, cereal bars, protein bars, meats (e.g., poultry, beef, pork, fish), textured vegetable protein, and medical foods.
Glycine or glycine analogs can be mixed with a food, dietary supplement, or beverage product, sprinkled onto a food, dietary supplement, or beverage product, or baked, compounded or otherwise incorporated into the food, dietary supplement, or beverage product.
Glycine or glycine analogs, according to the invention can be present in a partial or total meal replacement product such as a liquid product, semi-solid product, food product or dietary supplement product. A total meal replacement drink or food composition is a composition that is intended to replace one or more conventional meals per day. A partial meal replacement drink or food composition is a composition that is intended to replace part of one or more conventional meals per day. A partial or total meal replacement product is a product that contains glycine or glycine analogs according to the invention in an otherwise nutritionally balanced food or beverage product where the relative ratios of calories, protein, fat, saturated fat, carbohydrate, sugar, fiber and one or more vitamins and minerals are nutritionally balanced. Nutritionally balanced means that other than the glycine or glycine analog content, the relative proportions of calories, protein, fat, saturated fat, carbohydrate, sugar, fiber and one or more vitamins and minerals are as recommended by an appropriately recognized governmental or quasi-nongovernmental institution (e.g., United States Department of Agriculture).
Three exemplary food or beverage products containing glycine or glycine analogs include meal replacement powdered drink mixes, flavored drink mixes (e.g., low calorie, or sugar-free powder drink mix), and granola bars. A flavored drink mix can be a sugar-free flavored (e.g. berry or citrus flavored) drink mix that is added to 8-16 ounces of water and mixed. The flavored drink mix can comprise, for example, in descending order by weight, glycine, natural flavor, citric acid, maltodextrin, sucralose. The flavored drink mix can comprise about 7.5 grams of glycine in about 10 grams of drink mix.
A flavored meal replacement drink mix (e.g., chocolate, vanilla, or strawberry flavored) can be added to water (e.g., about 8 ounces of water, milk, or low-fat milk) and mixed. The drink mix can comprise, for example, in descending order by weight, glycine, maltitol, nonfat dried milk powder, milk protein concentrate, cocoa, sugar, natural flavor carrageenan, vitamin/mineral blend, solubilized milk protein, and sucralose. The drink mix can contain about 12.5 grams of glycine in about 45 grams of drink mix.
A flavored granola bar (e.g., berry, chocolate, peanut flavored) can comprise, for example, in descending order by weight, granola mix, glycine, fractionated palm oil, rice syrup, whey protein, isomalt, rice powder, inulin, sorbitol, almonds, sweetened cranberries, mixed berry powder, sweetened dried blueberries, anhydrous milkfat, nonfat dry milk natural flavors, citric acid, soybean lecithin, and salt. The granola bar can contain about 7.5 grams of glycine in about 50 grams of granola bar. Another embodiment of the invention provides a method of inducing apoptosis in a white adipocyte, in vivo or in vitro, comprising administering one or more glycine analogs or a combination of glycine and glycine analogs to the adipocyte.
Even another embodiment of the invention provides a method of reducing phosphorylation of BAD at amino acid position 136 in a white adipocyte, in vivo or in vitro, comprising administering a one or more glycine analogs or a combination of glycine and glycine analogs to the adipocyte.
Glycine can be added to an adipocyte at a concentration of about 5, 10, 50, 75, 100, 200, 300, 400, 500, 750, 1000 ng/ml or more.
The invention provides methods of treatment of lipomas or liposarcomas. Lipoma types include, e.g., angiolipoma, angiolipoleiomyoma, neural fibrolipoma, chondroid lipoma, spindle-cell lipoma, pleomorphic lipoma, intradermal spindle cell lipoma, hibernoma, and superficial subcutaneous lipoma. Glycine and/or glycine analogs can be used to treat lipomas or liposarcomas at injectable concentrations of about 0.1, 0.2, 0.5, 0.75, 1.0, 2.0, 2.5, 5.0, 7.5, 10.0, or 15.0 mg/ml or more. Alternatively, glycine and/or glycine analogs can be used to treat lipomas or liposarcomas at concentrations of about 15.0, 10.0, 7.5, 5.0, 2.5, 2.0, 1.0, 0.75, 0.5, 0.2, 0.1 mg/ml or less or any range between 15 and 0.1 mg/ml. Glycine and glycine analogs can be present at a concentration of about 0.5 1, 2, 3, 4, 5, 10, 15% or more or any range between about 0.5% and about 15%. Neutral glycine can be present in a solution of water or any pharmaceutically acceptable carrier. Glycine and/or glycine analogs can be administered parenterally, e.g., percutaneously, subcutaneously, intravascularly (e.g., intravenously), intramuscularly, intraarterial, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneally, transtracheal, subcuticular, subcapsular, subarachnoid, intraspinal, intrasternal, or intrathecaly injection or infusion, or topically or orally (as described above).
Glycine and/or glycine analogs can also be administered by direct injection into the lipoma or liposarcoma or injection into the area surrounding the lipoma or liposarcoma. Several divided dosages of glycine and/or glycine analogs, as well as staggered dosages, can be administered or the dose can be continuously infused, or can be a bolus injection or infusion. Furthermore, the dosages can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation. Treatment of a lipoma or liposarcoma means the reduction or elimination of the lipoma or liposarcoma.
Administration of glycine and/or glycine analogs can occur four, three, two, or one times a day. Administration can also occur four, three, two, or one time a week or three, two, or one time a month. Administration of can continue until the lipoma or liposarcoma shrinks 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% (by weight or volume), or until the lipoma or liposarcoma is eliminated.
All patents, patent applications, and other scientific or technical writings referred to anywhere herein are incorporated by reference in their entirety. The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms, while maintaining their ordinary meanings. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.
In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.
Rats were randomly divided, caged separately, and fed water ad libitum and diet TD 80406 diet (Harlan Teklad, Madison, Wis.). The diet composition is shown in Table 1. The TD 80406 diet has about 1-2% glycine present in the lactalbumin component and is considered a non-supplemented diet.
Adult (180 day old) male Fisher rats were randomly assigned in treatment groups of 10 rats in each group to diets comprising 5% or 20% glycine in their feed or a non-supplemented diet. See
Five rats from each treatment group were chosen at random and euthanized on day 30 of the study. Measurements of the abdominal fat content of each rat were obtained at necropsy (
The identical experiment was performed with female adult (180 day old) Fisher rats. The results obtained were generally similar except that the effect of glycine was actually somewhat more pronounced in the females than in the males, both in regard to weight loss and abdominal fat content (
Food consumption measurements were obtained on the indicated days of study. See
Blood samples were withdrawn from the tail vein of the rats under study and sent to Charles River Laboratories for Mutli-Analyte Profile testing. The results of these tests indicated that those rats on a high glycine diet exhibited statistically significant (p≦0.05) reduction in their serum triglyceride, HDL and cholesterol levels. These results correspond with results in the literature by others performing research with glycine. See, Hafidi et al., Glycine intake decreases plasma free fatty acids, adipose cell size, and blood pressure in sucrose fed rats. Am J Physiol Regul Integr Comp Physiol, 2004. 287(6):R1387-93; Aust et al., The hypolipaemic action of a glycine rich diet in rats. Nahrung, 1980. 24(7):663-71; Sugiyama et al., Dietary sulfur-containing amino acids and glycine as determinant factors in plasma cholesterol regulation in growing rats. J Nutr Sci Vitaminol (Tokyo), 1985. 31(1):121-5; Senthilkumar et al., Glycine modulates hepatic lipid accumulation in alcohol-induced liver injury. Pol J Pharmacol, 2003. 55(4):603-11; Park et al., Dietary taurine or glycine supplementation reduces plasma and liver cholesterol and triglyceride concentrations in rats fed a cholesterol-free diet. Nutrition Research, 1999. 19(12):1777-1789; Yoshida et al., Effects of addition of arginine, cystine, and glycine to the bovine milk-simulated amino acid mixture on the level of plasma and liver cholesterol in rats. J Nutr Sci Vitaminol (Tokyo), 1988. 34(6):567-76; Olson et al., Effect of amino acid diets upon serum lipids in man. Am J Clin Nutr, 1970. 23(12):1614-25; Ryzhenkov et al., [Hypolipidemic activity of glycine and its derivatives]. Vopr Med Khim, 1984. 30(2):78-80; Yagasaki et al., Effects of dietary methionine, cystine, and glycine on endogenous hypercholesterolemia in hepatoma-bearing rats. J Nutr Sci Vitaminol (Tokyo), 1986. 32(6):643-51; Emi et al., Missense mutation (Gly—Glu188) of human lipoprotein lipase imparting functional deficiency. J Biol Chem, 1990. 265(10):5910-6. Decrease in leptin levels, trending toward significance were observed, as would be expected when white adipose tissue (WAT) is decreased. Adiponectin levels were observed to increase in a manner trending towards significance as would be expected when WAT is decreasing. The data demonstrated that a high glycine diet resulted in a positive effect on these biomarkers of pathogenicity of obesity.
Adult male Zucker diabetic fatty (ZDF) rats were randomly assigned in treatment groups of 3 rats in each group to diets comprising 20% glycine in their feed or a non-supplemented diet. ZDF rats are obese, hyperlipidemic, and insulin resistant. Weight measurements were obtained on the indicated day of the study. See
Adult female Sprague-Dawley rats were randomly assigned in treatment groups of 3 rats in each group to diets comprising 5, 10, 15, or 20% glycine in their feed or a non-supplemented diet. See
Adult female Sprague-Dawley rats were randomly assigned in treatment groups of 3 rats in each group to diets comprising 5, 10, 15, or 20% glycine in their feed or a non-supplemented diet. See
Adult female Sprague-Dawley rats were randomly assigned in treatment groups of 3 rats in each group to diets comprising 5, 10, 15, or 20% glycine in their feed or a non-supplemented diet. The rats in each treatment group were euthanized on day 30 of the study. Measurements of the abdominal fat content of each rat were obtained at necropsy. See
Sprague Dawley rats, 24 days old, were fed a diet of 15% glycine and 85% TD80406. No gross lesions or treatment related abnormalities other than weight were reported at necropsy of animals fed diet containing 15% glycine and 85% TD80406 for 6 weeks. No differences in blood chemistry and complete blood counts were observed between control animals fed 100% TD80406 and animals fed a diet containing 15% glycine and 85% TD80406 for 6 weeks. Histopathological examination of tissues harvested from one animal fed a diet supplemented with high glycine was performed. A microscopic examination of trimmed, processed, embedded, microtomed, and hematoxylin and eosin stained tissues revealed no remarkable results for the brain, lung, liver, adrenal gland, kidneys, urinary bladder, heart, stomach, large intestine, or small intestine. In short, there were no microscopic changes from normal histology.
Adult male Sprague-Dawley rats were randomly assigned in treatment groups of 3 rats in each group to diets comprising 5% or 20% of glycine in their feed or a non-supplemented diet. On day 20 of the study the animals were euthanized and the adipose tissue obtained at necropsy. Total proteins were extracted from the adipose tissue. In order to demonstrate that adipose tissue derived from rats fed a high glycine diet underwent apoptosis, extracts of animals fed control or glycine-containing diets were assayed for the ability to phosphorylate BAD at position 136. As seen in
The data clearly demonstrated a dose dependent decrease in the phosphorylation of BAD at tyrosine 136, indicating that a high glycine diet leads to apoptosis in adipose tissue.
Assay of the tissue extracts for the ability to phosphorylate BAD at serine position 136 was performed as follows: One mg of tissue extract was added to BAD agarose (Upstate, Waltham, Mass.). The reaction volume was adjusted to 1 ml using RIPA buffer (with anti-phosphatases and anti-proteases) (Tris-HCl [pH 7.4] 50 mM; NP-40 1%; Na deoxycholate 0.25%; NaCl 150 mM; EDTA 1 mM; PMSF 1 mM; Protease Arrest 100 ul; sodium orthovanadate 1 mM; sodium fluoride 1 mM) and incubated for 0.5 hr at 30° C. The agarose beads were collected by centrifugation (5 sec at 12,000×g). The supernatant was removed and the beads washed 3× with ice cold TBS. The BAD-agarose was resuspended in 40 μl of sample buffer, boiled for 5 min, and centrifuged (5 min at 12,000×g). Seven microliters of sample were electrophoresed on a 15% gel (Tris-Glycine). The protein was transferred by western blotting to a nitrocellulose membrane and blocked with 5% NFM in TTBS at 4° C. with shaking. The membrane was washed with 2% NFM in TTBS. Each lane was blotted with rabbit anti-phospho-BAD 136 antibody at (1:1000 in 2% NFM/TTBS) for 2 hrs at room temperature. The blots were washed three times for 5 min with TTBS. The blots were incubated with goat anti-Rabbit-HRP (1:5000 in 2% NFM/TTBS). The blots were washed 3× for 5 min with TTBS and 2×5 min with TBS. Visualization of phosphorylated BAD was accomplished with a chemiluminesence substrate (Pierce Super-Signal Substrate™).
In order to further elucidate the mechanism of action by which glycine elicits the observed biological effects we used 2D-Differential in Gel Electrophoresis (2D-DIGE). 2D-DIGE is a powerful method that allows for the rapid assessment of differences in expression in proteomes of tissues from differing biological states. See, Patton, Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci, 2002. 771(1-2):3-31; Unlu et al., Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis, 1997. 18(11):2071-7; Von Eggeling et al., Fluorescent dual colour 2D protein gel electrophoresis for rapid detection of differences in protein pattern with standard image analysis software. Int J Mol Med, 2001. 8(4):373-7.
Preliminary results of dual labeling experiments of the proteins extracted from tissue obtained from control (
2D-DIGE analysis of adipose tissue from female Sprague-Dawley rats fed either a control diet or diet supplemented with 20% glycine by weight. Tissue samples were homogenized on ice using a PowerGen 125 Model FTH115 Homogenizer fitted with 7×110 mini-Tip Reusable Generator Probes and the proteins extracted using a Total Protein Extraction (TPE) Kit (Genotech, 92-Weldon Parkway, St. Louis, Mo. 63043-9989 U.S.A.) according to the protocol supplied with the kit. All buffers contained Protease Arrest Cocktail (Genotech, 92-Weldon Parkway, St. Louis, Mo. 63043-9989 U.S.A.) in order to minimize protein degradation during extraction and storage prior to use. The extracted proteins were precipitated using Bio Rad 2D cleanup kit (Cat.#163-2130) and resuspended in Cy labeling buffer (30 mM Tris-HCl pH 8.5, 4% CHAPS, 8M urea). Equal amounts of protein (50 ug) obtained from the control animals and treated animals were each labeled with 400 pmol of Cy3 or Cy5 fluorophore diluted in DMF according to manufacturer's specifications. Labeling reactions were carried out in the dark for 30 min on ice and quenched by addition of 1 mM lysine. The two populations of labeled proteins were mixed with Biolyte ampholytes (Bio Rad cat.#163-1112) and rehydration buffer (Bio Rad cat. #163-2083). The mixture was then loaded onto rehydrated IPG strips (Bio Rad Cat.#163-2099) over night at room temperature. The proteins in the rehydrated IPG strips were focused on a Biorad Protean IEF Gel apparatus and run in the 2nd dimension on a Bio Rad Protean Slab Gel apparatus according to the manufacturer's instructions. Visualization of the Cy3 and Cy5 labeled proteins in the gels was undertaken using a KODAK Image Station 2000 MM using 535 and 620 nm excitation and 600 and 670 nm emission filters respectively.
The development of pharmacokinetic and pharmacodynamic models for glycine with respect to reduction of adipose tissue mass will require an accurate method for the measurement of the concentration of the administered glycine. Ideally, the method will be capable of following the adsorption, distribution, metabolism and excretion (ADME) of the administered glycine exclusive of endogenous glycine. Additionally, the method developed should be capable of being easily modified for application to future studies with the glycine analogs. A LC/MS method can be used for this purpose. This approach allows the utilization of C13-Glycine in studies enabling the simultaneous determination of the ADME of dosed C13-Glycine and endogenous glycine.
In brief, the methodology consists of a sample clean-up step wherein proteins and nucleic acid contaminants are removed by acid precipitation prior to analysis by LC/MS. QC-samples are prepared prior to the initiation of each study containing known amounts of glycine/C13-Glycine in sample matrix (i.e. plasma or dialyzed tissue extract from untreated animals). Acid precipitation of the samples will be accomplished by the addition of 100 μl of an ice-cold 10% (vol/vol) perchloric acid containing 1% metaphosphoric acid to 100 μl of a plasma sample in a brown 1.5 ml microcentrifuge tube that is incubated on ice for 10 min prior to centrifugation at 12,000×g for 5 min at 4° C. The resultant supernatant will then be filtered through a 0.2 μm filter and dried in vacuo on a Savant SC110 Speedvac (or equivalent). The study and QC sample will be stored at −80° C. until being subjected to analysis. Prior to analysis the samples will be warmed to room temperature and reconstituted in 50 μl of deionized LC/MS grade water (LC/MS-ddH20) and transferred into glass autoinjector vials that then will be loaded onto the Micro AS (Thermo Electron) autoinjector. Twenty μl of each sample will be injected onto a 50×2.1 mm Hypercarb™ Column (Thermo Electron Corporation) on a Surveyor Plus HPLC System (Thermo Electron Corp.) coupled to a LCQ DECA XP Ion Trap Mass Spectrometer (Thermo Electron Corp.) via an ESI (Electro Spray Ionization) source. Chromatographic separation will be achieved by running a gradient from 20 mM perfluoropentanoic acid in LC/MS-ddH20 to 15% acetonitrile in LC/MS-ddH20 in 10 min, then to 26% acetonitrile in LC/MS-ddH20 in an additional 10 min and then to a final 50% acetonitrile in LC/MS-ddH20 over 10 min. Conditions will be held at the final 50% acetonitrile and 20 mM perfluoropentanoic acid in LC/MS-ddH20 for 10 min followed by a return to 100% 20 mM perfluoropentanoic acid in LC/MS-ddH20 for 5 min prior to the next injection.
The following experimental design can be used to determine the pharmacokinetic profile and oral bioavailability of glycine. Adult (180 day-old) Sprague-Dawley rats with surgically implanted jugular vein catheters and weighing between 200-225 g from Charles River Laboratories can be used. Eighteen rats will be randomly divided in 3 groups of 6 rats (3 male 3 female) and will be assigned at random to each of three dosage groups: High (5 mg/kg), Medium (2.5 mg/kg), and Low (0.25 mg/kg). Preliminary analysis of plasma samples obtained at necropsy after a 24 hr fast from male ZDF rats fed a diet consisting of 20% glycine by weight indicated a 16.9 μg/mL level of glycine. The actual steady state level of glycine was probably appreciably higher prior to the animals being fasted. Our chosen doses should result in peak plasma levels of ˜150 μg/ml, High Dose Group, 75 μg/ml, Medium Dose Group and 7.5 μg/ml Low Dose Group. Glycine will be dissolved in phosphate buffered saline (PBS), pH 7.2 and will be administered first via IV bolus. Plasma samples (0.1 ml) will be drawn into light blue top vacutainer tubes containing citrate (BD #363080) at the following time points T=0 min, T=0.5 min, T=1 min, T=5 min, T=15 min, T=30 min, T=1 hr, T=2 hr, T=4 hr, T=8 hr, T=6 hr T=24 hr and T=4 hr. The separated plasma collected at each time point will be flash frozen in liquid nitrogen and stored at −80° C. until analyzed. Animals will be allowed to recover for a period of seven days, reweighed and then treated with High, Medium and Low Dosages of glycine by oral gavage. Plasma samples, 0.1 ml, will be drawn as previously described for the IV bolus administration into a light blue topped vacutainer at the following time points. T=0 min, T=30 min, T=1 hr, T=2 hr T=4 hr, T=6 hr, T=8 hr, T=16 hr T=24 hr, T=48 hr, T=72 hr and T=96 hr. The separated plasma collected at each time point will be flash frozen in liquid nitrogen and stored at −80° C. until analyzed. Data will be analyzed using WinNonlin® version 4.1 software for Pharmacokinetic analysis. The pharmacokinetic model resulting from these experiments will be used to design the multiple dosing regimens to be used in subsequent experiments. Additionally, this model will serve as a base model for use in selecting analogs for further development.
In our preliminary studies, glycine was administered orally as part of the normal diet of the test animals. This method of administration did not provide accuracy and reproducibility of dosing necessary for construction of a pharmacodynamic model of glycine's action with respect to induction of apoptosis in adipose tissue. In order to undertake this work we must develop a dosing regimen that will allow us to accurately reflect the observed pharmacologic effect (i.e. induction of apoptosis in adipose tissue). The pharmacokinetic parameters obtained in our studies to define the single dose pharmacokinetic profile and oral bioavailability of high dose glycine will be used to design multiple dosing regimens for high dose glycine. The regimen that is developed will be used to maintain glycine at levels in the blood of test animals at levels equal to ±10% of those observed in animals that were fed a diet consisting of 20%, 10% and 5% glycine by weight in their diet. A detailed description of the number of animals in each dosage group and timing of samples will be determined based on the pharmacokinetic parameters and the variability of parameters ascertained from the previous single-dose studies. We, however, anticipate that the study design would require less than 10 animals (5 male, 5 female) per dosage group in order to validate the regimen. We will use the simulation function of WinNonlin® in the design of the dosing regimen and to develop the time points at which to sample in order to obtain the data to be used to validate the regimen.
WinNonlin® software provides an excellent set of tools for utilizing simulation in the design of multiple dosing schedules and sampling schemes to validate the dosing schedule. GraphPad StatMate version 2.00 for Windows will be used to confirm that the number of animals in each dosage group is that required to achieve proper power in order to demonstrate statistical validity. Statistical analysis will be performed using GraphPad InStat version 3.06 32 bit for Windows. The dosing regimen will be considered to be valid if the PK parameters and circulating levels of glycine in the blood are demonstrated not to differ in a statistically significant manner from those obtained experimentally.
Study animals will be euthanized and necropsies performed at the end of study. The phosphorylation state of BAD at ser-136 in the adipose tissue will be determined either by immunoprecipitation and western blot analysis with anti-BAD ser-136 antibody or by affinity capture LC/MS analysis. See, Papac & Shahrokh, Mass spectrometry innovations in drug discovery and development. Pharm Res, 2001. 18(2):131-45; Creaser et al., Immunoaffinity chromatography combined on-line with high-performance liquid chromatography-mass spectrometry for the determination of corticosteroids. J Chromatogr A, 1998. 794(1-2):37-43; Gallo et al., Development of a liquid chromatography/electrospray tandem mass spectrometry method for confirmation of chloramphenicol residues in milk after alfa-1-acid glycoprotein affinity chromatography. Rapid Commun Mass Spectrom, 2005. 19(4):574-9. The adipose tissue will also be subjected to immunohistochemical staining for the TUNEL protein as a marker of active apoptosis. See, Pavlovsky & Vagunda, [Apoptosis—selected methods of detection of apoptosis and associated regulatory factors on tissue sections of tumors]. Cesk Patol, 2003. 39(1): p. 6-10; Heatwole, V. M., TUNEL assay for apoptotic cells. Methods Mol Biol, 1999. 115:141-8; Stadelmann & Lassmann, Detection of apoptosis in tissue sections. Cell Tissue Res, 2000. 301(1):19-31.
Major organs will also be harvested and observed for any overt signs of toxicity and preserved for further analysis if any overt signs of toxicity are found.
Pharmacodynamics refers to the relationship between drug concentration at the site of action and the pharmacologic response, including biochemical and physiologic effects that influence that interaction. See, Shargel & Yu, Applied Biopharmaceutics and Pharmacokinetics. 4th ed. 1999, New York: McGraw-Hill. 573-605.
The form of the pharmacodynamic model is dependent on the mechanism by which the drug asserts its pharmacologic action. Thus, the information obtained in this model will provide useful information in regard to how glycine elicits its biologic effect in adipose tissue. In our preliminary studies we demonstrated that a high glycine diet resulted in BAD at ser-136 being in a dephosphorylated state. We propose to use the phosphorylation state of BAD at ser-136 as a marker of apoptosis for our pharmacodynamic modeling. We will build a PK/PD Link model for glycine action with respect to its effect on the phosphorylation state of BAD. A PK/PD Link model assumes fixed pharmacokinetic parameters in order to model the local concentration of drug at the site of action to be used by the PD model. Jusko, Corticosteroid pharmacodynamics: models for a broad array of receptor-mediated pharmacologic effects. J Clin Pharmacol, 1990. 30(4):303-10; Dayneka et al., Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm, 1993. 21(4):457-78. We will use the pharmacokinetic model derived from the single-dose and multiple dose studies to supply the fixed PK parameters for the PK/PD Linked model. Ex-vivo organ culture of white adipose tissue (WAT) will be used to model the PD portion of the PK/PD Linked model. The methods and procedures for establishing ex-vivo cultures of WAT are well described. See, Moustaid-Moussa & Fried, Culture of Adipose Tissue and Isolated Adipocytes, in Adipose Tissue Protocols, G. Ailhaud, Editor. 2001, Humana Press, Inc.: Totowa, N.J. p. 197-213; Livingston et al., Insulin-dependent regulation of the insulin-sensitivity of adipocytes. Nature, 1978. 273(5661):394-61; Bernstein, Improved insulin responsiveness in rat adipose tissue pieces cultured with charcoal-treated albumin and oxygen. J Lipid Res, 1982. 23(2):360-3; Bernstein, Insulin insensitivity and altered glucose utilization in cultured rat adipose tissue. J Lipid Res, 1979. 20(7):848-56; Maloff et al., Direct effects of growth hormone on insulin action in rat adipose tissue maintained in vitro. Endocrinology, 1980. 107(2):538-44. WAT organ cultures will be used in these experiments, as opposed to isolated adipocytes, because organ cultures more fully reflect the complex biology of WAT resulting in a PD model of concentration versus effect that is more reflective of the in vivo state. Papac & Shahrokh, Mass spectrometry innovations in drug discovery and development. Pharm Res, 2001. 18(2):131-45.
In brief, WAT will be obtained within 10 minutes of euthanasia by surgical excision of the retroperitoneal, inguinal, and gonadal fat pads from each of 3 male and 3 female Sprague-Dawley rats weighing 200-225 g. Approximately 12-15 gm of WAT will be obtained from each animal. The WAT from animals of the same sex will be combined and coarsely minced in conical plastic centrifuge tubes (3 g per tube) containing sterile, room temperature M199 (Gibco-BRL; liquid, bicarbonate buffered, supplemented with glutamine and 25 mM HEPES) and 50 μg/mL gentamicin. All further processing of the material will be performed in an aseptic fashion in a laminar flow hood as described by Fried and Moustaid-Moussa (Culture of Adipose Tissue and Isolated Adipocytes, in Adipose Tissue Protocols, G. Ailhaud, Editor. 2001, Humana Press, Inc.: Totowa, N.J. p. 197-213). The AT will be further minced into 5-10 mg fragments using sharp scissors. Once the tissue is finely minced it can remain at RT for up to 1 h (while the other tubes of tissue are being minced). The tissue will not be placed at 37° C., to avoid increasing its metabolic rate at this juncture. The WAT organ cultures will then be washed free of lipid droplets and blood by pouring the contents of each of the tubes through a nylon mesh (affixed to a funnel), which will be placed on top of a ˜500 mL bottle. This will be followed with a wash of at least 300 mL sterile Phosphate Buffered Saline (PBS), at 37° C., over the tissue on the funnel. The washed tissue will then be placed in a sterile tared Petri dish and any large blood clots removed with forceps. The tared Petri dish containing the WAT organ culture will be closed in order to maintain sterility, and then weighed. The WAT will then be placed equally (˜0.5 g wet weight/well) into 6 well tissue culture plates using forceps or a perforated spoon. Fresh M199 (Gibco-BRL; liquid, bicarbonate buffered, supplemented with glutamine and 25 mM HEPES) and 50 μg/mL gentamicin will then be immediately added and the cultures maintained in a humidified, 37° C. incubator under an atmosphere of 5% CO2-95% air for 48 hours in order to insure the absence of contamination and sterility.
Triplicate wells containing WAT organ cultures derived from male and female Sprague-Dawley rats prepared as described above will be washed 3× with fresh M199 (Gibco-BRL; liquid, bicarbonate buffered, supplemented with glutamine and 25 mM HEPES), and 50 μg/mL gentamicin The experiment will be initiated by the addition of fresh M199 medium supplemented with the following concentration of glycine. Control wells will receive fresh medium with no additional glycine added, experimental wells will receive M199 medium supplemented with glycine at five equally spaced concentrations with the highest concentration equal to twice the circulating level of glycine in the blood of the highest dose group of the multiple dose PK study. The media will be replenished on a daily basis for a period of 3 days. The cultures will then be harvested and washed 5 times with ice cold PBS. Samples will be prepared for quantification of glycine by the LC/MS method as previously described.
Dietary glycine at high levels (20% by weight) results in significant weight loss. This weight loss may be a result of the ability of glycine to induce apoptosis in WAT. This is based on preliminary data demonstrating that protein extracts obtained from WAT of treated animals did not have the ability to phosphorylate BAD at serine position 136 (
The mechanism by which weigh loss occurs has remained unexplained. We believe that glycine has a direct biochemical effect on WAT via regulation of the phosphorylation state of BAD leading to the induction of apoptosis. This is based on the observations in our preliminary experiments that no such dephosphorylation of BAD at ser-136 was observed in BAT or no significant loss of BAT tissue occurred. In addition, we observed that high concentrations of glycine in the medium of 3T3-L1 cells differentiated into adipocytes demonstrated increased staining for TUNEL when compared to non-treated cells. See, Heatwole, TUNEL assay for apoptotic cells. Methods Mol Biol, 1999. 115:141-8. An aim of this example is to develop a rapid bioassay that can be used to screen for bioactive analogs of glycine.
We have found that female Sprague-Dawley rats are particularly sensitive to the effects of high glycine in the diet, experiencing rapid significant weight loss. Thus, it would be possible to use significant weight loss in female Sprague-Dawley rats to screen for activity of analogs of glycine. However, this assay is time consuming, would require large-scale synthesis of analogs and would not be efficient for screening large numbers of compounds. We propose to develop a rapid biological in vitro test using differentiated 3T3-L1 cell lines and measurements of the phosphorylation state of BAD at ser-136. Gaillard et al., Growth of preadipocyte cell lines and cell strains from rodents in serum free hormone-supplemented medium. In Vitro, 1984. 20(2):79-88.
In order for such an assay to be used with confidence we will demonstrate that adipocytes from differentiated 3T3-L1 cells respond to high glycine levels in a manner similar to adipocytes in vitro. The following experiments are aimed at demonstrating the utility and validity of using dephosphorylation of BAD at Ser 136 in differentiated 3T3-L1 cells for this purpose.
Adipocytes from WAT will be obtained by modification of the purification process described above for organ culture of WAT. In brief, the WAT will be isolated as previously described and subjected to the following additional steps to obtain isolated adipocyte and stromal-vascular fractions. Isolated adipocyte and stromal fractions will be obtained by subjecting the minced WAT to digestion with Type I Collagenase at a concentration of 1 mg/ml in M199 media at 37° C. for 60 min. The collagenase-treated tissue will then be filtered through a sterile nylon filter (350 μm mesh) into a sterile centrifuge tube. This suspension will be centrifuged at 500×g for 1 min resulting in the separation of the stromal-vascular fraction (pellet) from the adipocyte containing fraction. The respective cell fractions will be washed three additional times in Hank's Balanced Salt Solution. The respective adipocyte and stromal-vascular fractions will then be counted, diluted with fresh M199 media and plated into the wells of six-well culture plates. The cells will be incubated overnight in a 37° C. incubator under an atmosphere of 5% CO2-95% air. The cells will be observed to insure viability and lack of contamination and the experiment will be initiated by the addition of fresh M199 media supplemented with the following increasing concentrations of glycine in the media. Control wells will receive fresh media with no additional glycine added, experimental wells will receive M199 media supplemented with glycine at the same concentrations of glycine used for the PD experiments. The media will be replenished on a daily basis for a period of 3 days. The cultures will then be harvested and washed 5 times with ice cold PBS. The cells will be lysed by exposure to a hypotonic buffer, clarified by centrifugation and aliquots of lysate instantly frozen in liquid nitrogen for storage at −80° C. until use. The intracellular glycine content of the samples will be determined by the LC/MS method. The phosphorylation state of BAD at Ser-136 will be determined either using an ELISA for BAD-Ser 136 or by affinity capture LC/MS analysis. Triplicate wells of each sample condition will be plated and immunohistochemical staining for TUNEL will be performed to demonstrate active apoptosis. We believe the following experiments will provide conclusive evidence that glycine acts directly on adipocytes derived from WAT.
3T3-L1 cells will be grown in culture and differentiated into adipocytes by standard methodology. See, Negrel & Dani, Cultures of Adipose Precursor Cells and Cells of Clonal Lines from Animal White Adipose Tissue, in Adipose Tissue Protocols, G. Ailhaud, Editor. 2001, Humana Press, Inc.: Totowa, N.J. p. 225-227. Prior to initiation of the experiment the 3T3-L1 adipocytes will be trypsinized and washed 5 times in dDMEM [containing 1 g/L glucose and 110 mg/L Na pyruvate, supplemented with 3.7 g/L Na bicarbonate, 33 μM biotin, 17 μM pantothenate, antibiotics (62 mg/L penicillin and 50 mg/L streptomycin or 10 mg/L tetracycline), 17 nM insulin and 2 nM T3 and 10% FBS]. Cells will be plated into the wells of six well culture plates at a density of 8.5×103 m cells/c2. The cells will be observed to insure viability and lack of contamination and the experiment will be initiated by the addition of fresh dDMEM media supplemented with the following increasing concentrations of glycine in the media. Control wells will receive fresh media with no additional glycine added, experimental wells will receive dDMEM media supplemented with glycine at the same concentrations of glycine as used for the PD experiments. The media will be replenished on a daily basis for a period of 3 days. The cultures will then be harvested and washed 5 times with ice cold PBS. The cells will be lysed by exposure to a hypotonic buffer, clarified by centrifugation and aliquots of lysate instantly frozen in liquid nitrogen for storage at −80° C. until use. The intracellular glycine content of the samples will be determined by the LC/MS method. The phosphorylation state of BAD at Ser-136 will be determined either using an ELISA for BAD-Ser 136 or by affinity capture LC/MS analysis. Preliminary experiments indicate that glycine at concentrations in the media equivalent to 2× the normal circulating levels in the blood cause 3T3-L1 adipocytes to undergo apoptosis as evidenced by positive TUNEL staining. Triplicate wells of each sample condition will be plated and immunohistochemical staining for TUNEL will be performed to demonstrate active apoptosis.
The utility of adipocytes derived from differentiation of 3T3-L1 cells will be further verified by demonstrating that the patterns of differentially expressed proteins elicited with glycine treatment is similar to the pattern seen in glycine-treated WAT protein extracts using 2D-gel and ICAT analysis. See, Patton et al., Two-dimensional gel electrophoresis; better than a poke in the ICAT? Curr Opin Biotechnol, 2002. 13(4): p. 321-8.
In brief, WAT and 3T3-L1 derived adipocytes will be obtained as previously described. Control and concentration of glycine in experimental wells will be treated as described above. Samples for analysis will be prepared as previously described and equal amounts of samples will be subjected to analysis by 2D-Gel and ICAT analysis in order to demonstrate the 3T3-L1 adipocytes and WAT derived adipocytes are responding in a biologically equivalent manner to glycine treatment. Analysis by ICAT can provide a starting point for elucidating the mechanism of action by which glycine induces apoptosis in adipocytes form WAT. ICAT is a powerful method capable of identifying which proteins differ between glycine and treated cells in a quantifiable fashion. The ICAT methodology is presented diagrammatically in
Glycine is a readily available, non-toxic amino acid. Glycine, glycine analogs, or a combination thereof should induce weight loss through the induction of apoptosis in WAT. The following series of glycine analogs can be synthesized:
The Formula I series can be synthesized, for example, by the following scheme:
The amino sulfonic acid analogs proposed in the above scheme will be synthesized by treating various dialkyl amines such as dimethyl amine with chloro-methanesulfonic acid. The Formula II series can be synthesized by, for example, by the following scheme:
The above shown analogs will be synthesized by treating dialkylamines or primary amines with Oxo-acetic acid methyl ester under reductive conditions using sodium cyanoborohydride as the reducing agent. The products will be purified by chromatography. Formula III can be synthesized by, for example, the following scheme:
The free carboxy terminus of N(alkyl) or N,N-Dialkyl glycine will be amidated with an amine in the presence of Dicylcohexyl carbodiimide (DCC) and dimethylaminopyridine (DMAP). In all cases the products will be purified by chromatography. The identity, purity and quantity will be ascertained by mass spectrometry, NMR, analytical liquid chromatography and any other analytical methodology as required.
The synthesized analogs will be subjected to a primary screen for their ability to promote the dephosphorylation of BAD at Ser-136. The analog will be screened at the same concentration with a no-glycine supplemented control and positive control of glycine in the media at the same concentration and at a known effective concentration. All assays will be performed in triplicate. All potential positive analogs will be subjected to a repeat screening. Secondary screening of identified positive compounds in in vitro tests to ascertain their chemical properties make them good drug candidates for in vivo testing.
In one working example, adult (180 day old) male Fisher rats were randomly assigned into treatment groups of 3 rats in each group to diets comprising 0.1%, 0.25%, 0.5%, 2%, 3.5% or 5% amino methane sulfonic acid (“AMS”) in their feed or a non-supplemented diet. Water and food consumption and animal weight measurements were obtained throughout the 26-day study. Rats consuming a non-supplemented diet showed a 6.6% weight gain over the course of the 26-day study, while rats fed a 3.5% AMS diet were statistically lighter and showed a 0.6% average weight gain, and rats fed a 5% AMS diet had a 2.8% loss from their baseline body weight. No significant differences were observed between groups in the amounts of food or water consumed throughout the course of the experiment. Measurements of the abdominal fat content of each rat were obtained at necropsy. A decrease in % body fat was observed with AMS supplemented diets and this decrease was directly related to the amount of AMS in the diet. Rats fed a 3.5% or 5% AMS diet had statistically significant (p≦0.05) less abdominal fat than those that were fed a non-supplemented diet. The average % body fat of the control group was 3.62%, while the average % body fat for the 3.5% and 5% AMS groups were 1.59% and 1.12%, respectively.
The following prophetic example is provided to illustrate the present invention. It should be understood, however, that the spirit and scope of the invention is not to be limited to the specific conditions or details described in this example but should only be limited by the scope of the claims.
Using known techniques (e.g., diagnosis by a medical professional), an animal (e.g., a human, dog, cat, horse, etc.) in need of treatment for lipoma or liposarcoma can be identified. A therapeutically effective amount of glycine and/or glycine analogs can be administered parenterally, e.g., percutaneously, subcutaneously, intravascularly (e.g., intravenously), intramuscularly, intraperitoneally or intrathecaly injection, by infusion techniques, orally, or by any other suitable administration method.
At intervals during the treatment regimen, the animal is monitored for signs and symptoms of lipoma or liposarcoma. After the treatment period has concluded, again using known techniques, the animal is found to have decreased signs and symptoms of lipoma or liposarcoma and/or to be no longer in need for treatment or reduced treatment for lipoma or liposarcoma. The lipoma or liposarcoma size is reduced by about 5. 10, 25, 50, 75, or 100% or any range between about 5% and 100%.
This application is a continuation-in-part of U.S. Ser. No. 11/265,414, filed Nov. 2, 2005, which claims the benefit of U.S. Ser. No. 60/624,228, filed on Nov. 2, 2004. This application is also a continuation-in-part of PCT/US2010/024562, filed on Feb. 18, 2010, which claims the benefit of U.S. Ser. No. 61/153,798, filed Feb. 19, 2009. All of these applications are incorporated herein by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| 60624228 | Nov 2004 | US | |
| 61153798 | Feb 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11265414 | Nov 2005 | US |
| Child | 13212574 | US | |
| Parent | PCT/US2010/024562 | Feb 2010 | US |
| Child | 11265414 | US |
